- Home
- IFN vs AVIR Comparison
IFN vs AVIR Comparison
Compare IFN & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | IFN | AVIR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.2M | 399.3M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | IFN | AVIR |
|---|---|---|
| Price | $11.76 | $4.74 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 135.3K | ★ 352.9K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.72 | $2.78 |
| 52 Week High | $15.95 | $6.45 |
Technical Indicators
Market Signals| Indicator | IFN | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 59.02 | 52.80 |
| Support Level | $11.40 | $4.61 |
| Resistance Level | $11.79 | $4.92 |
| Average True Range (ATR) | 0.13 | 0.29 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 79.31 | 84.48 |
Price Performance
Historical ComparisonAbout IFN India Fund Inc. (The)
India Fund Inc is a non-diversified closed-end management investment company. The fund's investment objective is long-term capital appreciation, which it seeks to achieve by investing in the equity securities of Indian companies. The company's portfolio is a non-diversified closed-end management investment company across various sectors such as financials, consumer staples, information technology, materials, healthcare, consumer discretionary, industrials, telecommunication services, utilities, and others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.